Using Eribulin and Radiation Before Surgery for Liposarcoma
Author Information
Author(s): Davis Lara, Zhu Limin, Mayo Skye C., Latour Emile, Park Byung, Huang Wei, Moloney Brendan, Davis Jessica L., Wakeman Kristina, Sheppard Brett, Billingsley Kevin G., Vetto John, Valenzuela Cristian D., Eil Robert L., Rocha Flavio, Hung Arthur, Ryan Christopher W.
Hypothesis
Can combining eribulin with radiation improve treatment outcomes for patients with resectable retroperitoneal liposarcoma?
Conclusion
The study found that the combination of eribulin and radiation is safe and should be further evaluated for treating resectable retroperitoneal liposarcoma.
Supporting Evidence
- Fifteen patients were enrolled in the study.
- Thirteen patients were evaluable for dose-determination.
- The recommended phase 2 dose of eribulin was established as 1.4 mg/m2.
- The median recurrence-free survival was 30.4 months.
- The median overall survival was 54.1 months.
Takeaway
Doctors tested a new treatment for a type of cancer called liposarcoma, and it seems safe to use before surgery.
Methodology
Patients received preoperative intensity-modulated radiation therapy with escalating doses of eribulin in an open-label dose-finding study.
Limitations
The study had a small sample size and was primarily focused on safety rather than efficacy.
Participant Demographics
Patients with primary or recurrent resectable retroperitoneal liposarcoma.
Statistical Information
Confidence Interval
95% CI 12.0-NR for recurrence-free survival; 95% CI 9.5-NR for overall survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website